First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial

被引：2

作者：

Aix, Santiago Ponce ^{[1
]}

Park, Keunchil ^{[2
]}

Tan, Eng-Huat ^{[3
]}

O'Byrne, Kenneth ^{[4
,5
]}

Zhang, Li ^{[6
]}

Boyer, Michael ^{[7
]}

Mok, Tony ^{[8
]}

Hirsh, Vera ^{[9
]}

Yang, James Chih-Hsin ^{[10
,11
]}

Maerten, Angela ^{[12
]}

Paz-Ares, Luis ^{[1
]}

机构：

[1] Hosp 12 Octubre, Oncosur, Cnio, Madrid, Spain

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[3] Natl Canc Ctr, Singapore, Singapore

[4] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia

[5] Queensland Univ Technol, Brisbane, Qld, Australia

[6] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[7] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[8] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab South China, Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China

[9] McGill Univ, Fac Med, Montreal, PQ, Canada

[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[11] Natl Taiwan Univ, Taipei, Taiwan

[12] Boehringer Ingelheim Pharma GmbH & Co KG, Ta Oncol, Ingelheim, Germany

来源：

关键词：

afatinib; gefitinib; EGFR; non-small-cell lung cancer;

D O I：

10.1016/j.jtho.2016.08.056

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.34

引用

页码：S203 / S204

页数：3